QELBREE
NDC 17772-132 · Supernus Pharmaceuticals, Inc
Generic nameviloxazine hydrochloride
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
Active ingredient(s)VILOXAZINE HYDROCHLORIDE
Strength150 mg/1
Pharmacologic classCytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]
Marketing categoryNDA
Packages
17772-132-01 — 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-01)
17772-132-07 — 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-07)
17772-132-30 — 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-30)
17772-132-60 — 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-60)
17772-132-90 — 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-90)
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
17772-131 — viloxazine hydrochloride, 17772-133 — viloxazine hydrochloride